Bone morphogenetic proteins and Dickkopf-1 in ankylosing spondylitis

References

• Khan MA, Van Der Linden SM. Ankylosing spondylitis and other spondyloarthropathies. Rheum Dis Clin North Am 1990;16:551–79.
   PubMed Web of Science ®Google Scholar
• Zochling J, Brandt J, Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford) 2005;44:1483–91.
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, Emery P, McGonagle D. The concept of disease modification in spondyloarthropathy. J Rheumatol 2002;29:1583–5.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X. Imaging of axial spondyloarthritis including ankylosing spondylitis. Ann Rheum Dis 2011;70(Suppl 1):i97–103.
   PubMed Web of Science ®Google Scholar
• Lories RJ, Luyten FP. Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev 2005;16:287–98.
   PubMed Web of Science ®Google Scholar
• Lories RJ, Luyten FP. Bone morphogenetic proteins in destructive and remodeling arthritis. Arthritis Res Ther 2007;9:207.
   PubMed Web of Science ®Google Scholar
• Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571–9.
   PubMed Web of Science ®Google Scholar
• Hsu WK, Wang JC. The use of bone morphogenetic protein in spine fusion. Spine J 2008;8:419–25.
   PubMed Web of Science ®Google Scholar
• Park MC, Park YB, Lee SK. Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis. Scand J Rheumatol 2008;37:200–4.
   PubMed Web of Science ®Google Scholar
• Lories RJ, Luyten FP, De Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 2009;11:221.
   PubMed Web of Science ®Google Scholar
• Baron R, Rawadi G. Target of the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocriology 2007;148:2635–43.
   PubMed Web of Science ®Google Scholar
• Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156–63.
   PubMed Web of Science ®Google Scholar
• Polzer K, Diarra D, Zwerina J, Schett G. Inflammation and destruction of the joints – the Wnt pathway. Joint Bone Spine 2008;75:105–7.
   PubMed Web of Science ®Google Scholar
• Van Der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
   PubMed Web of Science ®Google Scholar
• Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281–5.
   PubMed Web of Science ®Google Scholar
• Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996;35:66–71.
   PubMedGoogle Scholar
• Calin A, Mackay K, Santos H, Brophy S. A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index. J Rheumatol 1999;26:988–92.
   PubMed Web of Science ®Google Scholar
• Creemers MC, Franssen MJ, Van’t Hof MA, Gribnau FW, Van De Putte LB, Van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127–9.
   PubMed Web of Science ®Google Scholar
• Braun J, Pham T, Sieper J, Davis J, Van Der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817–24.
   PubMed Web of Science ®Google Scholar
• Wendling D, Cedoz J-P, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007;74:304–5.
   PubMed Web of Science ®Google Scholar
• Joo YB, Bang SY, Kim TH, Shim SC, Lee S, Joo KB, et al. Bone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitis. Plos One 2014;9:e104966.
   PubMed Web of Science ®Google Scholar
• Chen H-A, Chen C-H, Lin Y-J, Chen P-C, Chen W-S, Lu C-L, et al. Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. J Rheumatol 2010;37:2126–32.
   PubMed Web of Science ®Google Scholar
• Lories R. The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol 2011;7:700–7.
   PubMed Web of Science ®Google Scholar
• Carter S, Braem K, Lories RJ. The role of bone morphogenetic proteins in ankylosing spondylitis. Ther Adv Musculoskelet Dis 2012;4:293–9.
   PubMedGoogle Scholar
• Urist MR. Bone: formation by autoinduction. Science 1965;150:893–9.
   PubMed Web of Science ®Google Scholar
• Corr M. Wnt signaling in ankylosing spondylitis. Clin Rheumatol 2014;33:759–62.
   PubMed Web of Science ®Google Scholar
• Haroon N. Ankylosis in ankylosing spondylitis: current concepts. Clin Rheumatol 2015;34:1003–7.
   PubMed Web of Science ®Google Scholar
• Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, et al. Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2010;69:592–7.
   PubMed Web of Science ®Google Scholar
• Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 2012;32:2523–7.
   PubMed Web of Science ®Google Scholar
• Rossini M, Viapiana O, Idolazzi L, Ghellere F, Fracassi E, Troplini S, et al. Higher level of Dickkopf-1 is associated with low bone mineral density and higher prevalence of vertebral fractures in patients with ankylosing spondylitis. Calcif Tissue Int 2016;98:438–45.
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010;62:150–8.
   PubMed Web of Science ®Google Scholar
• Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751–64.
   PubMed Web of Science ®Google Scholar
• Wanders A, Van Der Heijde D, Landewé R, Béhier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756–65.
   PubMed Web of Science ®Google Scholar
• Haroon N, Kim T-H, Inman RD. NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Ann Rheum Dis 2012;71:1593–5.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71:1616–22.
   PubMed Web of Science ®Google Scholar
• Goodman S, Ma T, Trindade M, Ikenoue T, Matsuura I, Wong N, et al. COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res 2002;20:1164–9.
   PubMed Web of Science ®Google Scholar
• Kroon F, Landewé R, Dougados M, Van Der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:1623–9.
   PubMed Web of Science ®Google Scholar
• Konstantinidis I, Papageorgiou SN, Kyrgidis A, Tzellos TG, Kouvelas D. Effect of non-steroidal anti-inflammatory drugs on bone turnover: an evidence-based review. Rev Recent Clin Trials 2013;8:48–60.
   PubMedGoogle Scholar
• Van Esch RW, Kool MM, Van As S. NSAIDs can have adverse effects on bone healing. Med Hypotheses 2013;81:343–6.
   PubMed Web of Science ®Google Scholar
• Simon AM, Manigrasso MB, O’Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963–76.
   PubMed Web of Science ®Google Scholar
• Chang J-K, Wang G-J, Tsai S-T, Ho M-L. Nonsteroidal anti-inflammatory drug effects on osteoblastic cell cycle, cytotoxicity, and cell death. Connect Tissue Res 2005;46:200–10.
   PubMed Web of Science ®Google Scholar
• Vuolteenaho K, Moilanen T, Moilanen E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin Pharmacol Toxicol 2008;102:10–14.
   PubMed Web of Science ®Google Scholar